MOTS-c Side Effects: What Is Documented, What Is Reported, and What Is Unknown

The MOTS-c side effect profile has a peculiar shape. There is one controlled human trial, and it reported almost nothing. There is a list of adverse effects compiled by an anti doping agency from people who bought the peptide online, and it is longer and more alarming. There is a mechanism that predicts a few things neither source mentions. And there is no long term data of any kind.

This page sorts what is known by where it came from, because a side effect from a placebo controlled trial and a side effect from a forum post are not the same kind of fact. Research use only, and nothing here is medical advice. For what the compound is claimed to do rather than what it might cost, the MOTS-c benefits page covers the evidence; for the reported protocols, the dosage page.

The Evidence, Sorted by Quality

What the Human Trial Reported

MOTS-c itself has never been given to people in a registered trial. The nearest thing is CB4211, a modified analog developed by CohBar, which went through a phase 1a/1b study registered as NCT03998514 and completed in April 2021: single and multiple ascending doses in 65 healthy adults, then 20 obese adults with non alcoholic fatty liver disease randomised to 25 mg once daily by subcutaneous injection or placebo for four weeks, eleven on drug and nine on placebo. The primary endpoint, safety and tolerability, was met with no serious adverse events; the one specific adverse effect disclosed was transient, mild to moderate injection site reactions in more than 10% of those receiving it. Liver enzymes and glucose fell relative to placebo while liver fat did not separate, which the benefits page goes through.

Three limits on reading that as a MOTS-c safety record. It was four weeks. It was 20 people, of whom 11 got the drug. And it was a different molecule, engineered for better stability, at a dose of 25 mg a day that is many times higher than the reported research protocols and might therefore have surfaced effects those protocols never would, or missed effects that a weaker native peptide over months could produce. It is the best data there is, and it is thin.

What USADA Collected

The US Anti-Doping Agency publishes a page on MOTS-c because it is a prohibited substance and athletes ask about it. It lists adverse effects reported by people claiming to have bought MOTS-c online: increased heart rate or heart palpitations, injection site irritation, insomnia, local or generalised immune reactions, and fever. USADA adds that there is no data on long term use and that it is unknown under what conditions, if any, MOTS-c is safe, because no completed human clinical trials of the peptide exist.

The list deserves to be taken seriously and read carefully. These are self reports from people using unregulated product, so they capture everything that can go wrong with a grey market injectable, not only what the peptide does. Fever and immune reactions are the classic signature of endotoxin or a poorly purified peptide and would be expected from a bad vial of anything; palpitations and insomnia are harder to attribute, and could be the compound, a contaminant, or the usual noise of people starting a new protocol and paying attention to their bodies. None of it comes with a denominator, so nobody knows whether these happen to one user in five or one in five hundred.

What the Mechanism Predicts

MOTS-c works, in the 2015 Lee paper, by inhibiting the folate cycle, which throttles purine synthesis, piles up the AMP mimic AICAR, and switches on AMPK in skeletal muscle. A 2018 follow-up added that under metabolic stress it enters the nucleus and regulates stress response genes. Each part of that suggests something worth watching for, even though none of it has been observed in a person.

Glucose lowering and stacking

AMPK activation in muscle increases glucose uptake, which is the benefit. In the CB4211 trial glucose fell 6% against placebo in four weeks. On its own, in someone with normal glucose regulation, that is not a hypoglycaemia risk on any evidence available. Stacked with a GLP-1 or GIP/GLP-1 compound, which is a combination that turns up in forums, it is a combination that has never been studied in anyone. The general peptide side effects page covers the incretin compounds' own glucose effects.

The early fatigue reports

The most common forum report is a flat, tired first week or two. There is a plausible story behind it: AMPK activation shifts muscle toward fat oxidation and away from glucose, and switching fuel sources is not instant. There is also a less plausible story, circulating on social media, that inhibiting the folate cycle depletes folate and causes fatigue or brain fog. The folate effect in the paper was measured inside cells overexpressing MOTS-c, not as a systemic folate deficiency in an animal, and nothing published shows MOTS-c lowering blood folate in anything. Treat the fatigue as a real report with an unconfirmed cause, and treat the folate depletion claim as a hypothesis someone should test rather than a finding.

Cell growth and the long term question

Two published observations sit awkwardly next to each other. In metabolically stressed myoblasts, MOTS-c roughly doubled survival and increased proliferative capacity about sixfold once the stress was removed (Reynolds JC et al., Nat Commun 2021;12:470). And senescent human fibroblasts, the cells that accumulate with age, turned out to carry elevated MOTS-c, with added MOTS-c modestly increasing some components of their inflammatory secretory profile (Kim SJ et al., Aging 2018, doi 10.18632/aging.101463). Neither is evidence of harm. Both are reasons why a peptide that promotes cell survival under stress and talks directly to nuclear transcription factors is not something anyone should assume is neutral over years. The long term data does not exist, and the pharmacology does not make its absence reassuring.

The Sex Difference in the Data

This is the finding most side effect pages miss. An East Asian mitochondrial DNA variant, m.1382A>C, changes one amino acid in MOTS-c and produces a less active peptide. In a meta analysis of 27,527 people, men carrying it had a higher prevalence of type 2 diabetes and women did not, and in the same paper high fat fed male mice injected with MOTS-c lost weight and improved glucose tolerance while female mice were unaffected (Zempo H et al., Aging 2021;13:1692, doi 10.18632/aging.202529). The paediatric study that found lower MOTS-c in obese children found the difference only in boys.

The straightforward reading is that MOTS-c biology is sex dependent in a way nobody has explained, and that the mouse benefit data, which is overwhelmingly from male animals, may not transfer to women at all. The ovariectomised mouse studies that get cited for post menopausal bone and metabolic benefit are the exception, and they are a specific model of oestrogen loss rather than a study of intact females. The peptides for women page discusses that gap. It is not a side effect in the usual sense, but a compound that may do less in half the population changes the risk to benefit arithmetic for that half.

Banned in Sport

MOTS-c is named explicitly on the WADA prohibited list under section S4.4.1, activators of AMP-activated protein kinase, alongside AICAR itself. It is prohibited at all times. Detection methods have been published, and USADA's page exists precisely because athletes are asking. For anyone subject to testing, a positive result is the most certain adverse outcome of using MOTS-c, and it does not depend on dose.

Regulatory Status

MOTS-c is not approved for human use anywhere. The FDA placed it in Category 2 of its interim bulk substances scheme in September 2023, the category for nominated compounds with identified safety concerns, citing the lack of clinical data on efficacy or safety. In April 2026 the agency removed it from that list and referred it to the Pharmacy Compounding Advisory Committee, which on 23 July 2026 voted 7 to 5 with two abstentions to recommend it for the 503A compounding list, with FDA staff having recommended against. That is a recommendation, not an approval, and the staff objection was on exactly the point this page is about: the human safety data is thin. The PCAC vote page has the record. The are peptides safe guide covers what an unapproved research compound status means in practice.

Reducing the Avoidable Risks

Most of what is on USADA's list is at least as likely to come from the vial as from the peptide. That part is controllable.

• Buy from a vendor that publishes batch specific testing. Fever, immune reactions and site inflammation are what endotoxin and impurities produce. A certificate of analysis with purity, endotoxin and sterility results on the actual batch is the single most effective thing available. The testing guide explains how to read one.
• Site rotation and technique. Site reactions were the one confirmed adverse effect in the controlled trial, and rotating sites and injecting correctly are what limit them. The injection guide covers rotation and depth.
• Do not stack it with a glucose lowering compound without a reason and a way to measure. The combination is unstudied and the mechanism overlaps.
• Block length. Four weeks is the outer limit of any human safety data. The reported research protocols run four to eight weeks, and the second half of that window is unmonitored territory, which is the argument for short blocks and a log that would catch anything unexpected.
• Do not use it in tested sport. There is no threshold and no argument.

For comparison, SS-31, the other mitochondrial peptide run alongside MOTS-c, has a safety record built on months of supervised daily dosing in clinical trials, and the trials that failed did so on efficacy rather than safety. The SS-31 page lays that out, and it is a useful benchmark for what a real safety record looks like next to this one.

Honest Status

Nothing in the available data suggests MOTS-c is acutely dangerous at the doses people report using, on the grounds that a related molecule at a far higher dose was well tolerated for a month and that nearly a decade of grey market use has not produced a pattern of serious harm that anyone has documented. That is a weak kind of reassurance, built on absence of evidence rather than evidence of absence, and it says nothing about months of use, about women, about stacking, or about what a peptide that regulates nuclear gene expression does over years. The honest summary is that the short term profile looks mild and the long term profile is unknown, and that most of the alarming reports are more likely to be about product quality than about the peptide.

Key Takeaways

• No safety study of MOTS-c itself has been run in humans; the nearest is a four week trial of the analog CB4211 in 20 people, which was well tolerated with injection site reactions as the only disclosed adverse effect
• USADA lists palpitations, injection site irritation, insomnia, immune reactions and fever from people who bought it online, with no incidence and no product verification
• The mechanism predicts glucose lowering, which is a stacking concern rather than a standalone one, and gives the early fatigue reports some plausibility
• The folate depletion claim circulating online is a hypothesis, not a finding
• Human genetic data and mouse data both show a sex difference, with the peptide doing less or nothing in females
• It is banned by WADA at all times under S4.4.1 and not approved by any regulator
• Batch tested product, site rotation, no unmonitored stacking and short blocks remove most of the avoidable risk

Frequently Asked Questions

What are the most commonly reported MOTS-c side effects?

Injection site reactions come first in every source, including the one controlled human trial, where transient mild to moderate site reactions affected more than one in ten people on the analog CB4211. Beyond that, the effects USADA lists from people who bought MOTS-c online are increased heart rate or palpitations, insomnia, local or generalised immune reactions and fever. Fatigue in the first week or two is the most common forum report. None of those has a measured incidence.

Is MOTS-c safe?

Nobody can say, because no safety study of MOTS-c itself has been run in people. The nearest data is the CB4211 trial, where a modified analog given at 25 mg a day for four weeks to 20 obese adults met its safety endpoint with no serious adverse events, after a phase 1a in 65 healthy volunteers. That covers one month, one dose, one molecule that is not the one sold to researchers. Long term use has no data at all.

Can MOTS-c cause low blood sugar?

In mice it improves insulin sensitivity and raises muscle glucose uptake, and in the CB4211 trial glucose fell 6% against placebo. Nobody has documented hypoglycaemia from MOTS-c alone in a person with normal glucose regulation. The theoretical concern is stacking it with a GLP-1 compound or another glucose lowering agent, which no study has examined.

Does MOTS-c affect women differently from men?

The human genetic data says the peptide may matter more in men. A mitochondrial DNA variant that weakens MOTS-c raised diabetes prevalence in men but not women across 27,527 people, and in the same paper female mice did not respond to MOTS-c injection while males did. Whether that means women get less benefit, fewer side effects, or both, has not been tested.

Is MOTS-c banned in sport?

Yes. It is named explicitly on the WADA prohibited list under S4.4.1, activators of AMP-activated protein kinase, and it is prohibited at all times, in and out of competition. Detection methods exist. For a tested athlete that is the most certain consequence on this page.